Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook_2014     Display Documents



ID: 682237.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook_2014
Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations
Authors:Beck-Broichsitter, M.; Rieger, M.; Reul, R.; Gessler, T.; Seeger, W.; Schmehl, T.
Date of Publication (YYYY-MM-DD):2013-05
Journal Abbrev.:Eur J Pharm Biopharm
Volume:84
Issue / Number:1
Start Page:106
End Page:114
Audience:Not Specified
Abstract / Description:Liposomes have attracted extensive attention as inhalative drug delivery vehicles. The preparation of tailored liposomal formulations (i.e. nebulization stability and controlled drug release profiles) would facilitate new perspectives for the treatment of pulmonary diseases. 5(6)-Carboxyfluorescein (CF)-loaded submicron liposomal formulations with varying phase transition temperatures were prepared from lipid blends in different molar ratios. Their physicochemical properties, in vitro dye release, stability to nebulization (Aeroneb Pro) and ex vivo pulmonary dye absorption and distribution characteristics were investigated. Phase transitions of liposomes were adjusted below and above body temperature (32.9-55.2 degrees C). The amount of CF released from liposomes in vitro correlated well with their membrane fluidity. An increase in phase transition temperature resulted in an extended dye release profile. All formulations revealed aerodynamic particle sizes of approximately 4 mum with remarkable stability when nebulized by vibrating-mesh technology (percentage of encapsulated model drug approximately 80%). Analogous to the release results observed in vitro, liposomal formulations revealing phase transitions above body temperature displayed an increased pulmonary CF retention in an ex vivo lung model. Consequently, an in vitro-ex vivo correlation was established, which demonstrated an excellent agreement of the dye release results with the absorption profiles observed in the biological system (R(2) >/= 0.91). Overall, the concept of liposomal "phase transition release" is promising for controlled pulmonary drug delivery applications. The ex vivo technique enables a reliable determination of lung-specific pharmacokinetics of drug delivery vehicles, which enhances tailored carrier preparation and testing during early formulation development.
Free Keywords:Absorption/drug effects/physiology; Animals; Chemistry, Pharmaceutical/*methods; Delayed-Action Preparations/administration & dosage/chemistry/pharmacokinetics; Fluoresceins/administration & dosage/*chemistry/*pharmacokinetics; Liposomes; Lung/drug effects/*metabolism; Male; *Nebulizers and Vaporizers; Particle Size; Rabbits
External Publication Status:published
Document Type:Article
Communicated by:Svea Hümmer
Affiliations:MPI für physiologische und klinische Forschung
Identifiers:ISSN:1873-3441 (Electronic) 0939-6411 (Linking) %R 10.1016/j.ejpb.2012.12.003
URL:http://www.ncbi.nlm.nih.gov/pubmed/23262166
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.